Table 7.
The antitumor activity of extracts of Liagora hawaiiana against different cell lines.
| Cell line | Concentration (µg/ml) | Cell viability (%) |
||||||
|---|---|---|---|---|---|---|---|---|
| Total (Ethanol) | Lipoidal matters | Chloro-form | n-butanol | Aqueous | Powder | Vinblastine sulfate | ||
|
A-549 Lung carcinoma |
000.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 001.00 | 100 | 99.6 | 98.7 | 100 | 100 | 100 | 98.2 | |
| 002.00 | 99.8 | 94.8 | 95.2 | 100 | 100 | 100 | 94.7 | |
| 003.90 | 96.7 | 89.5 | 86.7 | 100 | 100 | 100 | 81.4 | |
| 007.80 | 90.3 | 70.4 | 79.5 | 100 | 98.1 | 100 | 73.8 | |
| 015.60 | 80.6 | 56.2 | 63.8 | 98.0 | 91.4 | 98.7 | 62.5 | |
| 031.25 | 68.5 | 38.7 | 40.8 | 86.9 | 79.5 | 94.3 | 40.7 | |
| 062.50 | 53.2 | 28.1 | 31.9 | 72.1 | 63.8 | 87.1 | 32.9 | |
| 125.00 | 34.9 | 22.4 | 23.5 | 50.6 | 45.9 | 69.2 | 25.2 | |
| 250.00 | 21.8 | 14.0 | 14.8 | 39.8 | 37.6 | 51.8 | 15.3 | |
| 500.00 | 09.79 | 06.1 | 06.9 | 26.5 | 24.9 | 32.7 | 06.8 | |
|
CACO-2 Intestinal carcinoma |
IC50 (µg/ml) | 73.6 ± 5.8 | 21.2 ± 1.6 | 25 ± 3.1 | 132 ± 11.4 | 111 ± 8.9 | 274 ± 26.2 | 24.6 ± 0.7 |
| 000.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| 001.00 | 100 | 93.7 | 100 | 100 | 100 | 100 | 99.2 | |
| 002.00 | 100 | 89.4 | 99.4 | 98.1 | 100 | 100 | 93.8 | |
| 003.90 | 100 | 78.1 | 96.3 | 91.7 | 99.7 | 100 | 86.2 | |
| 007.80 | 98.0 | 65.3 | 87.2 | 86.4 | 93.8 | 100 | 79.4 | |
| 015.60 | 90.6 | 38.4 | 70.9 | 75.3 | 85.2 | 98.3 | 67.5 | |
| 031.25 | 78.1 | 28.9 | 37.4 | 60.8 | 69.1 | 92.5 | 48.9 | |
| 062.50 | 65.9 | 20.4 | 28.6 | 45.1 | 48.7 | 81.4 | 31.4 | |
| 125.00 | 47.8 | 13.2 | 19.4 | 36.2 | 39.4 | 65.1 | 20.3 | |
| 250.00 | 31.7 | 06.7 | 10.5 | 23.6 | 27.8 | 41.8 | 08.9 | |
| 500.00 | 18.6 | 03.2 | 05.9 | 11.7 | 15.9 | 30.6 | 04.0 | |
| IC50 (µg/ml) | 118 ± 10.5 | 12.2 ± 0.6 | 25.4 ± 1.2 | 52.9 ± 3.3 | 60.5 ± 4.7 | 206 ± 16.2 | 30.3 ± 1.4 | |
|
HCT-116 Colon carcinoma |
000.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 001.00 | 100 | 96.7 | 91.4 | 100 | 100 | 100 | 66.4 | |
| 002.00 | 98.1 | 90.6 | 86.2 | 100 | 100 | 100 | 58.1 | |
| 003.90 | 94.2 | 83.9 | 78.1 | 100 | 99.4 | 100 | 47.3 | |
| 007.80 | 86.1 | 70.8 | 63.9 | 98.2 | 95.2 | 100 | 39.8 | |
| 015.60 | 71.8 | 52.3 | 50.6 | 92.4 | 88.7 | 99.4 | 28.7 | |
| 031.25 | 59.4 | 42.9 | 41.0 | 86.9 | 79.4 | 95.2 | 18.9 | |
| 062.50 | 36.7 | 33.9 | 31.7 | 72.8 | 65.9 | 86.1 | 15.5 | |
| 125.00 | 21.8 | 20.6 | 22.4 | 45.1 | 41.8 | 70.9 | 12.1 | |
| 250.00 | 12.9 | 13.2 | 12.9 | 36.2 | 28.7 | 42.1 | 06.7 | |
| 500.00 | 05.6 | 06.3 | 05.2 | 20.4 | 16.2 | 28.6 | 04.0 | |
| IC50 (µg/ml) | 44.2 ± 0.9 | 195 ± 0.7 | 16.6 ± 0.8 | 114 ± 9.2 | 104 ± 8.7 | 216 ± 12.3 | 3.5 ± 0.2 | |
|
HeLa Cervical carcinoma |
000.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 001.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| 002.00 | 100 | 99.7 | 98.6 | 100 | 100 | 100 | 98.1 | |
| 003.90 | 97.8 | 96.4 | 93.2 | 100 | 100 | 100 | 95.4 | |
| 007.80 | 90.3 | 90.6 | 85.4 | 100 | 100 | 100 | 90.6 | |
| 015.60 | 78.4 | 81.7 | 76.4 | 98.6 | 97.9 | 100 | 82.7 | |
| 031.25 | 63.1 | 69.4 | 62.1 | 91.7 | 90.6 | 100 | 71.9 | |
| 062.50 | 48.2 | 51.8 | 42.5 | 83.1 | 78.2 | 100 | 47.8 | |
| 125.00 | 31.5 | 36.7 | 30.4 | 70.8 | 65.1 | 99.7 | 34.5 | |
| 250.00 | 19.7 | 23.9 | 19.5 | 56.4 | 47.2 | 92.3 | 22.8 | |
| 500.00 | 08.3 | 14.5 | 08.7 | 38.6 | 31.5 | 81.6 | 09.1 | |
| IC50 (µg/ml) | 58.8 ± 1.4 | 70.2 ± 3.5 | 50.7 ± 2.9 | 340 ± 16.7 | 231 ± 20.1 | > 500 | 59.7 ± 2.1 | |
|
HepG-2 Hepatocellular carcinoma |
000.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 001.00 | 100 | 100 | 99.8 | 100 | 100 | 100 | 60.9 | |
| 002.00 | 100 | 99.2 | 93.1 | 100 | 100 | 100 | 54.2 | |
| 003.90 | 98.5 | 93.1 | 84.0 | 100 | 98.7 | 100 | 45.0 | |
| 007.80 | 90.1 | 85.7 | 69.5 | 100 | 93.1 | 100 | 34.1 | |
| 015.60 | 78.0 | 76.9 | 46.2 | 99.2 | 86.2 | 100 | 26.8 | |
| 031.25 | 65.4 | 60.8 | 32.8 | 94.0 | 75.3 | 100 | 19.2 | |
| 062.50 | 40.6 | 43.1 | 25.6 | 88.6 | 61.4 | 98.1 | 14.3 | |
| 125.00 | 28.3 | 30.4 | 14.3 | 73.1 | 43.0 | 91.8 | 10.9 | |
| 250.00 | 14.6 | 18.7 | 06.9 | 46.2 | 31.7 | 80.7 | 05.8 | |
| 500.00 | 06.8 | 10.2 | 03.4 | 28.9 | 19.4 | 68.9 | 03.2 | |
|
MCF-7 Breast carcinoma |
IC50 (µg/ml) | 50.8 ± 5.1 | 50.4 ± 4.3 | 14.4 ± 0.8 | 233 ± 19.6 | 101 ± 7.8 | > 500 | 2.9 ± 0.3 |
| 000.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| 001.00 | 100 | 100 | 97.2 | 100 | 100 | 100 | 67.1 | |
| 002.00 | 100 | 100 | 91.7 | 100 | 100 | 100 | 58.7 | |
| 003.90 | 100 | 100 | 85.0 | 100 | 100 | 100 | 52.9 | |
| 007.80 | 99.5 | 97.0 | 76.9 | 100 | 99.3 | 100 | 47.2 | |
| 015.60 | 91.4 | 89.5 | 60.8 | 100 | 95.1 | 100 | 40.5 | |
| 031.25 | 79.8 | 71.3 | 39.6 | 99.4 | 89.5 | 100 | 31.9 | |
| 062.50 | 45.1 | 49.8 | 28.1 | 96.5 | 70.8 | 98.2 | 23.8 | |
| 125.00 | 32.7 | 36.2 | 19.4 | 81.4 | 47.2 | 94.5 | 15.1 | |
| 250.00 | 19.4 | 21.4 | 08.7 | 63.1 | 35.9 | 83.1 | 07.8 | |
| 500.00 | 10.2 | 13.8 | 04.2 | 37.8 | 26.5 | 71.5 | 05.4 | |
| IC50 (µg/ml) | 58.1 ± 3.7 | 62.2 ± 6.1 | 23.6 ± 3.4 | 380 ± 17.9 | 118 ± 82.3 | > 500 | 5.9 ± 0.4 | |
|
PC-3 Prostate carcinoma |
000.00 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| 001.00 | 100 | 100 | 100 | 100 | 100 | 100 | 93.0 | |
| 002.00 | 100 | 98.6 | 98.0 | 100 | 100 | 100 | 88.2 | |
| 003.90 | 100 | 91.7 | 91.7 | 100 | 100 | 100 | 74.8 | |
| 007.80 | 100 | 84.3 | 84.1 | 100 | 98.7 | 100 | 68.9 | |
| 015.60 | 98.0 | 68.1 | 70.8 | 100 | 90.6 | 100 | 56.7 | |
| 031.25 | 90.6 | 47.2 | 41.5 | 99.5 | 82.1 | 98.4 | 37.8 | |
| 062.50 | 72.8 | 35.0 | 23.7 | 93.1 | 67.4 | 91.3 | 24.9 | |
| 125.00 | 47.8 | 23.6 | 19.5 | 86.4 | 46.2 | 80.1 | 13.7 | |
| 250.00 | 31.7 | 14.9 | 10.2 | 71.6 | 35.9 | 65.3 | 09.5 | |
| 500.00 | 18.9 | 06.3 | 06.3 | 46.8 | 21.3 | 41.9 | 05.3 | |
| IC50 (µg/ml) | 120 ± 9.3 | 29.2 ± 1.3 | 26.7 ± 1.4 | 469 ± 38.6 | 114 ± 10.5 | 414 ± 43.1 | 21.2 ± 0.9 | |
Values are expressed as mean ± SEM of 3 determinants.